stereotactic body radiation therapy using cyberknife® for liver metastases: a report from tianjin...
DESCRIPTION
Zhi-Yong Yuan, MD, PhD Chun-Lei Liu, MD Ma0-Bin Meng, MD, PhD CyberKnife Center, Department of Radiation Oncology, Tianjin Medical University Cancer Institute & HospitalTRANSCRIPT
![Page 1: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/1.jpg)
Tianjin Medical University Cancer Institute & HospitalHuanhuXi Road, TiYuanBei, He Xi District, Tianjin 300060, PRCTel: +86-22-23340123 Fax: + 86-22-23341405 Web site: www.tmucih.org
STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES:
A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL
Zhi-Yong Yuan, MD, PhDChun-Lei Liu, MD
Ma0-Bin Meng, MD, PhDCyberKnife Center, Department of Radiation Oncology,Tianjin Medical University Cancer Institute & Hospital
![Page 2: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/2.jpg)
2
Background
The liver is the second most common site for metastatic spread of cancer.
Surgical resection is currently considered as the first line measure for the treatment of liver metastatises (LM).
Hess KR, et al. Cancer 2006; 106: 1624-1633.
Timmerman RD, et al. CA Cancer J Clin 2009; 59: 145-170.
![Page 3: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/3.jpg)
3
Liver metastasis SBRT report
![Page 4: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/4.jpg)
4Hoyer M, et al. Int J Radiation Oncology Biol Phys 2012; 82: 1047-1057
![Page 5: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/5.jpg)
5
Questions and Aims
The optimal dose and fractionation scheme has not yet been determined.
It is still unclear whether it is scientifically rigorous enough to recommend its routine use for curative treatment of LM.
![Page 6: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/6.jpg)
6
CyberKnife Treatment System
The present study is aimed at assessing the efficacy and safety of SBRT using CyberKnife on the treatment of LM, It is anticipated that this study will provide additional evidence for clinical practice.
![Page 7: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/7.jpg)
7
Inclusion Criteria The inclusion criteria were defined as follows:
Patients of any age; LM Disease confirmed cytologically, pathologically, or
diagnosed through imaging; Patients with KPS ≥ 70; Patients within ≤ 4 LMs and individual tumor diameter <
6 cm; Patient’s life expectancy >3 months; Patient unsuitable for or refractory to surgery and
received CyberKnife treatment; Bilirubin less than 3 mg/dl, albumin greater than 2.5 g/dl,
and serum liver enzymes less than twice the upper limit of normal range.
![Page 8: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/8.jpg)
8
The dose constraints of SBRT
![Page 9: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/9.jpg)
9
Follow-up and endpoints
The patients were observed at 1 month after completion of treatment, then every 3 months for the first year, and every 6 months thereafter until July 2012.
The primary endpoint was local control (LC)
OS, PFS, distant PFS (DPFS), and adverse events. Local control of LM was assessed at a minimum
of 6 months of follow-up after CyberKnife treatment in order to avoid uncertainty associated with early transient radiographic changes within the high-dose region.
![Page 10: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/10.jpg)
10
Patient characteristics
![Page 11: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/11.jpg)
11
Summary of SBRT parameters
![Page 12: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/12.jpg)
12
Treatment characteristics
![Page 13: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/13.jpg)
13
Follow-up patients
Prior to RT 5 Weeks 3 Months 6 Months 13 Months 18 Months 25 Months
![Page 14: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/14.jpg)
14
LC rate, PFS, and DPFS
1 year LC: 94.4%2 years LC: 89.7%
Median PFS: 12 monthsMedian DPFS: 37 months
![Page 15: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/15.jpg)
15
LC rate by subgroups
![Page 16: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/16.jpg)
16
Overall survival
Median OS: 37.5 months1 year OS: 68.6 months2 years OS: 55.9 months
Median OS for favorable patients : Not reachedMedian OS for non-favorable patients: 8.7 months
Note: The favorable patients were defined as primaries originating from colorectal, breast, and stomach cancers, and sarcomas.
![Page 17: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/17.jpg)
17
OS rate by subgroups
![Page 18: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/18.jpg)
18
Factors associated with OS
![Page 19: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/19.jpg)
19
Patterns of failure
![Page 20: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/20.jpg)
20
Toxicities The treatment was well tolerated by all patients;
the most common toxicities were grade 1 or 2 fatigue, nausea, vomiting, and changes in liver function tests, which were corrected by routine treatment.
None of the patients developed grade 3 or higher toxicity. In addition, no clinically significant changes were noted in liver function evaluations or physical examinations of LM patients.
![Page 21: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/21.jpg)
21
Discussion The RT strategies:
The type of RT should be determined according to the Barcelona Clinic Liver Cancer (BCLC) stage and liver function.
![Page 22: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/22.jpg)
22
Discussion The dose and fractionation scheme :
The prescribed dose and fractionation were specified according to lesion Location and Volume in this study.
![Page 23: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/23.jpg)
23
Discussion The optimal dose and fractionation scheme :
29 patients: 40 Gy/4f13 patients: 45 Gy/3fLC: 45Gy/3f > 40Gy/4f
Vautravers DC, et al. Int J Radiation Oncology Biol Phys 2011; 81: e39-47
LC: 60Gy/5f > 50Gy/5f >30Gy/3f
Rule WR, et al. Ann Surg Oncol 2011; 18: 1081-1087
![Page 24: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/24.jpg)
24
Discussion The BED correlative with LC:
Chang DT, et al. Cancer 2011; 117: 4060-4069
Median prescription dose: 41.7Gy (22-60)Median fractions: 6 fractions (1-6)
Lanciano R, et al. Fron Oncol 2012; 2: 1-8
Median prescription dose/fraction: 12GyMedian fractions: 3 fractions (3-5)
![Page 25: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/25.jpg)
25
Discussion The LC correlative with tumor volume:
13 patients: < 60 Gy/3f36 patients: = 60 Gy/3f
Rusthoven KE, et al. JCO 2009; 27: 1572-1578
Median prescription dose/fraction: 12GyMedian fractions: 3 fractions (3-5)
Lanciano R, et al. Fron Oncol 2012; 2: 1-8
≠
![Page 26: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/26.jpg)
26
Limitations This is a retrospective study. As record keeping
and bias may influence results, prospective studies of LM must be performed to confirm the efficacy and safety of SBRT with CyberKnife.
LC appears to be excellent with CyberKnife, however, our follow-up is short and the study included a heterogeneous group of patients with various primary tumors, previous treatments, and liver disease statuses, etc.
The optimal dose and fractionation scheme has not yet been determined. Despite these limitations, the study showed that SBRT using CyberKnife can improve LC as well as OS in patients with LM.
![Page 27: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/27.jpg)
27
Conclusions
SBRT with CyberKnife is an effective modality with good local control and acceptable toxicity for unresectable or medically inoperable LM.
Such studies will hopefully also help identify the subset of patients most likely to benefit from this therapy.
Further study: Guideline for the SBRT Dose-Fraction for Different Volume and Sites LM lesions (Large number cases and Muticenter needed)
![Page 28: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/28.jpg)
THANKS
Tianjin Medical University Cancer Institute & Hospital
![Page 29: STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE® FOR LIVER METASTASES: A REPORT FROM TIANJIN CANCER INSTITUTE & HOSPITAL](https://reader034.vdocument.in/reader034/viewer/2022052504/553a52214a79599a678b4a88/html5/thumbnails/29.jpg)
Radiation Oncologist : Wang Ping, Song Yongchun, Zhuang Hongqing, Meng Maobing
Nerosurgeon : Wang Xiaoguang, Liuqun
Thoracic Surgeon
Wang Changli, Zhang Zhenfa
Belly Surgeon:
Hao Jihui, Song Tianqiang
Physicist :Li Fengtong, Dong Yong
TherapistWang Jingsheng, Chen Huaming
The TUMC Cyberknife Team
Acknowledgements F0unndations: NFSC (No. 81201754) and the
Cyberknife Foundation (No. 4-1-3).